Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K12 | Q12852 | 9/20 | 0.33 |
| ▸ | DLK1 | P80370 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23337914 | 1.00 | MAP3K12 (0.33) | MAP3K12DLK1OPRM1OPRL1 | |
| SCHEMBL23554427 | 0.89 | KAT2B (0.39) | — | |
| SCHEMBL19807290 | 0.89 | KAT2B (0.39) | — | |
| SCHEMBL18099727 | 0.89 | KAT2B (0.39) | — | |
| SCHEMBL10119950 | 0.88 | OPRM1 (0.38) | MAP3K12OPRM1OPRL1 | |
| SCHEMBL20756869 | 0.87 | KDM2B (0.33) | — | |
| SCHEMBL27423217 | 0.84 | TLR9 (0.34) | OPRM1OPRL1 | |
| SCHEMBL20756242 | 0.83 | OPRL1 (0.40) | OPRM1OPRL1 | |
| SCHEMBL10119953 | 0.83 | MAP3K12 (0.30) | MAP3K12 | |
| SCHEMBL20756541 | 0.82 | HRH3 (0.35) | OPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230065740-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230048132-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230065740-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | CDK2, CDK1, CCNK | MAP3K12 92/4885DLK1 641/4885OPRM1 4786/4885 |
| US-20230048132-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | CDK2, CDK1, CCNK | MAP3K12 92/4885DLK1 641/4885OPRM1 4786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.